{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T10:38:23Z","timestamp":1773657503334,"version":"3.50.1"},"reference-count":41,"publisher":"American Society of Hematology","issue":"3","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2001,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Interleukin 4 (IL-4) suppresses the growth of acute lymphoblastic leukemia (ALL) cells, but its clinical usefulness is limited by proinflammatory activity due mainly to the interaction of cytokine with endothelial cells and fibroblasts. Stroma-supported cultures of leukemic lymphoblasts were used to test the antileukemic activity of an IL-4 variant, BAY 36-1677, in which the mutations Arg 121 to Glu and Thr 13 to Asp ensure high affinity for IL-4R\u03b1\/IL-2R\u03b3 receptors expressed by lymphoid cells, without activation of the IL-4R\u03b1\/IL-13R\u03b1 receptors mainly expressed by other cells. BAY 36-1677 (25 ng\/mL) was cytotoxic in 14 of 16 cases of B-lineage ALL; the median reduction in cell recovery after 7 days of culture was 85% (range, 17%-95%) compared to results of parallel cultures not exposed to the cytokine. Twelve of the 14 sensitive cases had t(9;22) or 11q23 abnormalities; 3 were obtained at relapse. BAY 36-1677 induced apoptosis in leukemic lymphoblasts but did not substantially affect the growth of normal CD34+ cells, thus conferring a growth advantage to normal hematopoietic cells over leukemic lymphoblasts in vitro. BAY 36-1677 had antileukemic activity equal or superior to that produced by native IL-4, but it lacked any effects on the growth of endothelial cells and fibroblasts. The molecular manipulation of IL-4 to abrogate its proinflammatory activity has generated a novel and therapeutically promising cytokine for the treatment of high-risk ALL.<\/jats:p>","DOI":"10.1182\/blood.v97.3.752","type":"journal-article","created":{"date-parts":[[2002,7,27]],"date-time":"2002-07-27T12:46:47Z","timestamp":1027774007000},"page":"752-758","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":19,"title":["Interleukin-4 variant (BAY 36-1677) selectively induces apoptosis in acute lymphoblastic leukemia cells"],"prefix":"10.1182","volume":"97","author":[{"given":"Kleebsabai","family":"Srivannaboon","sequence":"first","affiliation":[{"name":"From the Departments of Hematology-Oncology and Pathology, St Jude Children's Research Hospital, and the University of Tennessee College of Medicine, Memphis, TN; and Molecular Technologies, Bayer Biotechnology, Berkeley, CA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Armen B.","family":"Shanafelt","sequence":"additional","affiliation":[{"name":"From the Departments of Hematology-Oncology and Pathology, St Jude Children's Research Hospital, and the University of Tennessee College of Medicine, Memphis, TN; and Molecular Technologies, Bayer Biotechnology, Berkeley, CA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabetta","family":"Todisco","sequence":"additional","affiliation":[{"name":"From the Departments of Hematology-Oncology and Pathology, St Jude Children's Research Hospital, and the University of Tennessee College of Medicine, Memphis, TN; and Molecular Technologies, Bayer Biotechnology, Berkeley, CA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla P.","family":"Forte","sequence":"additional","affiliation":[{"name":"From the Departments of Hematology-Oncology and Pathology, St Jude Children's Research Hospital, and the University of Tennessee College of Medicine, Memphis, TN; and Molecular Technologies, Bayer Biotechnology, Berkeley, CA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederick G.","family":"Behm","sequence":"additional","affiliation":[{"name":"From the Departments of Hematology-Oncology and Pathology, St Jude Children's Research Hospital, and the University of Tennessee College of Medicine, Memphis, TN; and Molecular Technologies, Bayer Biotechnology, Berkeley, CA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susana C.","family":"Raimondi","sequence":"additional","affiliation":[{"name":"From the Departments of Hematology-Oncology and Pathology, St Jude Children's Research Hospital, and the University of Tennessee College of Medicine, Memphis, TN; and Molecular Technologies, Bayer Biotechnology, Berkeley, CA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ching-Hon","family":"Pui","sequence":"additional","affiliation":[{"name":"From the Departments of Hematology-Oncology and Pathology, St Jude Children's Research Hospital, and the University of Tennessee College of Medicine, Memphis, TN; and Molecular Technologies, Bayer Biotechnology, Berkeley, CA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dario","family":"Campana","sequence":"additional","affiliation":[{"name":"From the Departments of Hematology-Oncology and Pathology, St Jude Children's Research Hospital, and the University of Tennessee College of Medicine, Memphis, TN; and Molecular Technologies, Bayer Biotechnology, Berkeley, CA."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"key":"2020021221081545100_B1","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1056\/NEJM199808273390907","article-title":"Drug therapy: acute lymphoblastic leukemia.","volume":"339","author":"Pui","year":"1998","journal-title":"N Engl J Med."},{"key":"2020021221081545100_B2","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1200\/JCO.2000.18.3.547","article-title":"Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia.","volume":"18","author":"Kantarjian","year":"2000","journal-title":"J Clin Oncol."},{"key":"2020021221081545100_B3","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1056\/NEJM198912283212612","article-title":"Potential long-term toxic effects in children treated for acute lymphoblastic leukemia.","volume":"321","author":"Meadows","year":"1989","journal-title":"N Engl J Med."},{"key":"2020021221081545100_B4","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1056\/NEJM199112123252402","article-title":"Acute myeloid leukemia in children treated with epi-podophyllotoxins for acute lymphoblastic leukemia.","volume":"325","author":"Pui","year":"1991","journal-title":"N Engl J Med."},{"key":"2020021221081545100_B5","first-page":"1680","article-title":"L-asparaginase may potentiate the leukemogenic effect of the epi-podophyllotoxins.","volume":"9","author":"Pui","year":"1995","journal-title":"Leukemia."},{"key":"2020021221081545100_B6","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1056\/NEJM199103213241205","article-title":"Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood.","volume":"324","author":"Lipshultz","year":"1991","journal-title":"N Engl J Med."},{"key":"2020021221081545100_B7","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/sj.leu.2400702","article-title":"Cranial irradiation is the major cause of learning problems in children treated for leukemia and lymphoma: a comparative study.","volume":"11","author":"Van Dongen-Melman","year":"1997","journal-title":"Leukemia."},{"key":"2020021221081545100_B8","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1084\/jem.155.3.914","article-title":"Identification of a T cell\u2013derived B cell growth factor distinct from interleukin 2.","volume":"155","author":"Howard","year":"1982","journal-title":"J Exp Med."},{"key":"2020021221081545100_B9","doi-asserted-by":"crossref","first-page":"9689","DOI":"10.1073\/pnas.83.24.9689","article-title":"Interleukin 4 mediates autocrine growth of helper T cells after antigenic stimulation.","volume":"83","author":"Fernandez-Botran","year":"1986","journal-title":"Proc Natl Acad Sci U S A."},{"key":"2020021221081545100_B10","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1182\/blood.V78.6.1574.1574","article-title":"Inhibitory effect of interleukin-4 on the in vitro growth of Ph1-positive acute lymphoblastic leukemia cells.","volume":"78","author":"Okabe","year":"1991","journal-title":"Blood."},{"key":"2020021221081545100_B11","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1172\/JCI116042","article-title":"Interleukin 4 inhibits in vitro proliferation of leukemic and normal human B cell precursors.","volume":"90","author":"Pandrau","year":"1992","journal-title":"J Clin Invest."},{"key":"2020021221081545100_B12","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1182\/blood.V83.7.1731.1731","article-title":"Interleukin-4 induces programmed cell death (apoptosis) in cases of high-risk acute lymphoblastic leukemia.","volume":"83","author":"Manabe","year":"1994","journal-title":"Blood."},{"key":"2020021221081545100_B13","doi-asserted-by":"crossref","first-page":"4797","DOI":"10.1182\/blood.V87.11.4797.bloodjournal87114797","article-title":"Interleukin-4 enhances the survival of severe combined immunodeficient mice engrafted with human B-cell precursor leukemia.","volume":"87","author":"Mitchell","year":"1996","journal-title":"Blood."},{"key":"2020021221081545100_B14","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1200\/JCO.1992.10.11.1802","article-title":"Phase I evaluation of thrice-daily intravenous bolus interleukin-4 in patients with refractory malignancy.","volume":"10","author":"Atkins","year":"1992","journal-title":"J Clin Oncol."},{"key":"2020021221081545100_B15","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/bjc.1992.243","article-title":"Recombinant human interleukin 4 (IL-4) given as daily subcutaneous injections\u2014a phase I dose toxicity trial.","volume":"66","author":"Gilleece","year":"1992","journal-title":"Br J Cancer."},{"key":"2020021221081545100_B16","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/0959-8049(93)90108-R","article-title":"Recombinant human interleukin-4 (rhu IL-4) administered by the intravenous and subcutaneous routes in patients with advanced cancer\u2014a phase I toxicity study and pharmacokinetic analysis.","volume":"29A","author":"Prendiville","year":"1993","journal-title":"Eur J Cancer."},{"key":"2020021221081545100_B17","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/00002371-199402000-00009","article-title":"Phase II studies of recombinant human interleukin-4 in advanced renal cancer and malignant melanoma.","volume":"15","author":"Margolin","year":"1994","journal-title":"J Immunother Emphasis Tumor Immunol."},{"key":"2020021221081545100_B18","doi-asserted-by":"crossref","first-page":"473","DOI":"10.3109\/07357909309018879","article-title":"Interleukin-4 and cancer therapy.","volume":"11","author":"Puri","year":"1993","journal-title":"Cancer Invest."},{"key":"2020021221081545100_B19","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1006\/clin.1997.4304","article-title":"Safety evaluation of recombinant human interleukin-4. II: clinical studies.","volume":"83","author":"Leach","year":"1997","journal-title":"Clin Immunol Immunopathol."},{"key":"2020021221081545100_B20","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1182\/blood.V77.9.1859.1859","article-title":"Interleukin-4: a prototypic immunoregulatory lymphokine.","volume":"77","author":"Paul","year":"1991","journal-title":"Blood."},{"key":"2020021221081545100_B21","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1146\/annurev.immunol.17.1.701","article-title":"The IL-4 receptor: signaling mechanisms and biologic functions.","volume":"17","author":"Nelms","year":"1999","journal-title":"Annu Rev Immunol."},{"key":"2020021221081545100_B22","doi-asserted-by":"crossref","first-page":"9454","DOI":"10.1073\/pnas.95.16.9454","article-title":"An immune cell-selective interleukin 4 agonist.","volume":"95","author":"Shanafelt","year":"1998","journal-title":"Proc Natl Acad Sci U S A."},{"key":"2020021221081545100_B23","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/0076-6879(87)54085-X","article-title":"Rapid and efficient site-specific mutagenesis without phenotypic selection.","volume":"154","author":"Kunkel","year":"1987","journal-title":"Methods Enzymol."},{"key":"2020021221081545100_B24","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1182\/blood.V95.2.535","article-title":"CD38 ligation inhibits normal and leukemic myelopoiesis.","volume":"95","author":"Todisco","year":"2000","journal-title":"Blood."},{"key":"2020021221081545100_B25","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1084\/jem.181.3.1101","article-title":"Ligation of CD38 suppresses human B lymphopoiesis.","volume":"181","author":"Kumagai","year":"1995","journal-title":"J Exp Med."},{"key":"2020021221081545100_B26","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1172\/JCI118474","article-title":"Stroma-supported culture in childhood B-lineage acute lymphoblastic leukemia cells predicts treatment outcome.","volume":"97","author":"Kumagai","year":"1996","journal-title":"J Clin Invest."},{"key":"2020021221081545100_B27","doi-asserted-by":"crossref","first-page":"3735","DOI":"10.1182\/blood.V89.10.3735.3735_3735_3744","article-title":"Prevalence and growth characteristics of malignant stem cells in B-lineage acute lymphoblastic leukemia.","volume":"89","author":"Nishigaki","year":"1997","journal-title":"Blood."},{"key":"2020021221081545100_B28","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1182\/blood.V91.3.1001","article-title":"Cyclosporin A induces apoptosis in childhood acute lymphoblastic leukemia cells.","volume":"91","author":"Ito","year":"1998","journal-title":"Blood."},{"key":"2020021221081545100_B29","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1200\/JCO.1998.16.3.907","article-title":"In vitro cytotoxicity of docetaxel in childhood acute leukemias.","volume":"16","author":"Consolini","year":"1998","journal-title":"J Clin Oncol."},{"key":"2020021221081545100_B30","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1182\/blood.V93.1.315","article-title":"Hyperdiploid acute lymphoblastic leukemia with 51 to 65 chromosomes: a distinct biological entity with a marked propensity to undergo apoptosis.","volume":"93","author":"Ito","year":"1999","journal-title":"Blood."},{"key":"2020021221081545100_B31","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1083\/jcb.66.1.188","article-title":"Rapid flow cytofluorometric analysis of mammalian cell cycle by propidium iodide staining.","volume":"66","author":"Krishan","year":"1975","journal-title":"J Cell Biol."},{"key":"2020021221081545100_B32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/(SICI)1097-0320(19970101)27:1<1::AID-CYTO2>3.0.CO;2-L","article-title":"Cytometry in cell necrobiology: analysis of apoptosis and accidental cell death (necrosis).","volume":"27","author":"Darzynkiewicz","year":"1997","journal-title":"Cytometry."},{"key":"2020021221081545100_B33","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1084\/jem.182.5.1545","article-title":"Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl.","volume":"182","author":"Martin","year":"1995","journal-title":"J Exp Med."},{"key":"2020021221081545100_B34","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1182\/blood.V79.9.2370.2370","article-title":"Bone marrow-derived stromal cells prevent apoptotic cell death in B-lineage acute lymphoblastic leukemia.","volume":"79","author":"Manabe","year":"1992","journal-title":"Blood."},{"key":"2020021221081545100_B35","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1182\/blood.V84.7.2253.2253","article-title":"Interleukin-13 inhibits the proliferation of normal and leukemic human B-cell precursors.","volume":"84","author":"Renard","year":"1994","journal-title":"Blood."},{"key":"2020021221081545100_B36","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1093\/intimm\/8.12.1915","article-title":"Biological activity of IL-4 and IL-13 on human endothelial cells: functional evidence that both cytokines act through the same receptor.","volume":"8","author":"Kotowicz","year":"1996","journal-title":"Int Immunol."},{"key":"2020021221081545100_B37","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1172\/JCI116015","article-title":"Human fibroblasts synthesize elevated levels of extracellular matrix proteins in response to interleukin 4.","volume":"90","author":"Postlethwaite","year":"1992","journal-title":"J Clin Invest."},{"key":"2020021221081545100_B38","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1093\/intimm\/10.10.1421","article-title":"IL-4 and IL-13 specifically increase adhesion molecule and inflammatory cytokine expression in human lung fibroblasts.","volume":"10","author":"Doucet","year":"1998","journal-title":"Int Immunol."},{"key":"2020021221081545100_B39","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1182\/blood.V75.3.611.611","article-title":"Bone marrow stromal cell regulation of B lymphopoiesis: interleukin-1 (IL-1) and IL-4 regulate stromal cell support of pre-B cell production in vitro.","volume":"75","author":"Billips","year":"1990","journal-title":"Blood."},{"key":"2020021221081545100_B40","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1126\/science.8372354","article-title":"IRS-1: essential for insulin- and IL-4-stimulated mitogenesis in hematopoietic cells.","volume":"261","author":"Wang","year":"1993","journal-title":"Science."},{"key":"2020021221081545100_B41","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1006\/jmbi.1994.0144","article-title":"Human interleukin-4 and variant R88Q: phasing x-ray diffraction data by molecular replacement using x-ray and nuclear magnetic resonance models.","volume":"247","author":"Muller","year":"1995","journal-title":"J Mol Biol."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/97\/3\/752\/1670926\/752.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/97\/3\/752\/1670926\/752.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,13]],"date-time":"2020-02-13T02:12:12Z","timestamp":1581559932000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/97\/3\/752\/52787\/Interleukin4-variant-BAY-361677-selectively"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,2,1]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2001,2,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.v97.3.752","relation":{},"ISSN":["1528-0020","0006-4971"],"issn-type":[{"value":"1528-0020","type":"electronic"},{"value":"0006-4971","type":"print"}],"subject":[],"published":{"date-parts":[[2001,2,1]]}}}